<!-- INVARIANT: examples are single-line HTML comments so a fresh template parses to total=0 (MEMORY_EMPTY). Do NOT un-comment or split across lines. t100 guards this. -->
> This file is kept up to date automatically while the stage runs. Add observations at the review step, not by editing here directly.

## Interpretations

- 2026-08-26T11:54:32Z — read the Q5/Q7 overlap as narrower-overrides-broader: Q7 makes the vendor doc authoritative for vendor detail, but Q5 explicitly re-opens orchestration, so Q5 governs orchestration and Q7 governs component vendors; resolved in the consolidated summary rather than as a follow-up question
- 2026-08-26T11:54:32Z — treated Sesame and Rumik as out of the competitor set despite BRIEF.md listing them as reference points; Sesame is consumer hardware and Rumik is a TTS supplier, so neither is a vendor a clinic would shortlist
<!-- example: 2026-05-29T10:14:32Z — chose REST over GraphQL; the consuming team only needs CRUD, revisit if subscriptions land -->

## Deviations

- 2026-08-26T11:54:32Z — the confirmed Q4 answer classifies multilingual as a differentiator, but GoTo ships 10+ languages with auto-detection at SMB pricing, so the claim would not survive a buyer conversation; recommended narrowing it to Indic code-switching as a proposal for the next stage rather than silently overriding the confirmed answer
- 2026-08-26T11:54:32Z — the ideation phase rule forbids implementation detail in ideation artifacts, but the stage mandates a build-vs-buy artifact that necessarily names orchestration frameworks; kept it at the build/buy decision level with component selection and design deferred to later stages
- 2026-08-26T11:54:32Z — declined to produce a SOM figure despite market sizing being a listed stage output; with a 4x spread in analyst estimates, no India clinic count, no India price point and no capture target requested, any number would have been invented
<!-- example: 2026-05-29T10:14:32Z — skipped the optional caching layer the stage prose suggested; the dataset is small enough that it adds risk -->

## Tradeoffs

- 2026-08-26T11:54:32Z — recommended LiveKit over Pipecat even though the two strongest India vendors (Exotel telephony, Rumik TTS) both ship Pipecat integrations; single-core economics are load-bearing for the 20-percent-per-pack business case, and a compliant managed on-ramp with an India region cannot be self-built, whereas adapters are bounded work
- 2026-08-26T11:54:32Z — reported the analyst sizing spread as the finding instead of picking one number; a single figure would have conveyed false precision to a reader building a plan on it
<!-- example: 2026-05-29T10:14:32Z — picked TDD over BDD this run; the team is unit-first and the domain is well-understood -->

## Open questions

- 2026-08-26T11:54:32Z — which practice-management/EHR systems the clients run is unknown and blocks the healthcare-depth half of the positioning; belongs in requirements with the pilot clinic, not further desk research
- 2026-08-26T11:54:32Z — no count of Indian private clinics was found, so the India bottom-up denominator is missing and any India-first argument currently rests on relative growth rates alone
- 2026-08-26T11:54:32Z — US practice consolidation (independent practices shrinking, 63.9 percent corporate-owned) cuts against an accessible-price SMB product; untested against AI Thinkers actual client base
- 2026-08-26T11:54:32Z — the LiveKit recommendation needs a time-boxed spike proving Exotel bidirectional streaming before it is treated as settled
<!-- example: 2026-05-29T10:14:32Z — confirm the retention window with compliance before the next stage hardens the schema -->
